MétaCan
Menu
Back to cohort
Record W2911538469 · doi:10.1093/ecco-jcc/jjy222.079

DOP45 Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial

2019· article· en· W2911538469 on OpenAlexaff
Niels Vande Casteele, K. Papamichael, Jenny Jeyarajah, Mark T. Osterman, Adam S. Cheifetz

Bibliographic record

VenueJournal of Crohn s and Colitis · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsRobarts Clinical Trials
Fundersnot available
KeywordsMedicineInfliximabInterquartile rangeCrohn's diseaseInternal medicinePost-hoc analysisLogistic regressionOdds ratioConfidence intervalReceiver operating characteristicArea under the curveConcordanceGastroenterologySurgeryDisease

Abstract

fetched live from OpenAlex

Therapeutic drug monitoring is used in clinical practice to optimise infliximab (IFX) therapy in patients with Crohn’s disease (CD). However, IFX induction concentration cut-points associated with early post-induction complete response in patients with fistulizing CD are unknown. We aimed to investigate the association of IFX serum concentrations at weeks (W)2, 6, and 14 with complete fistula response assessed at Week 14 (CFR14). We analysed data from the ACCENT-2 trial,1 which included 282 patients with active fistulizing CD treated with IFX. In this study, CFR14 was defined as a complete absence of draining fistulas. Receiver-operating characteristic curve analysis was performed to identify IFX concentration cut-points with combined maximal sensitivity and specificity that corresponded to CFR14. A multi-variable logistic regression analysis was performed to evaluate the association of IFX exposure, patient demographics, and disease characteristics with CFR14. In patients who achieved CFR14 compared with those who did not, the median [interquartile range, IQR] IFX concentrations were significantly higher at W6 (18.4 [12.7–27.8] μg/ml vs. 15.2 [9.1–26.0] μg/ml; p = 0.038) and W14 (6.4 [2.3–10.8] μg/ml vs. 3.7 [1.5–7.3] μg/ml; p = 0.001) (Table 1). IFX cut-points of 13.9 μg/ml at W6 and 4.8 μg/ml at W14 were associated with CFR14 (Table 2). Multivariable logistic regression analysis identified W14 IFX concentration as the only independent factor associated with CFR14 with an odds ratio [95% confidence interval] of 1.31 [1.06–1.61]; p = 0.013. Table 1. Serum infliximab concentration by efficacy outcome status. Table 2. Infliximab threshold concentration associated with CFR14. Higher IFX concentrations during induction are associated with early complete fistula response in patients with fistulizing CD. Early accelerated dosing of IFX in a subset of patients with subtherapeutic drug exposure may lead to better outcomes. Reference 1. This study, carried out under YODA Project #, (2017), -1276, used data obtained from the Yale University Open Data Access Project, which has an agreement with Janssen Research & Development, L.L.C. The interpretation and reporting of research using these data are solely the responsibility of the authors, and does not necessarily represent official views of the Yale University Open Data Access Project, or Janssen Research & Development, L.L.C.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.229
Teacher spread0.222 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Crohn s and ColitisSame topicInflammatory Bowel DiseaseFrench-language works237,207